BridgeBio Pharma, Inc. has grown revenue 401% a year over three years and 63% a year over five. Revenue growth, 3-year annual rate: +401% (Biotechnology median +17%). Revenue growth, 5-year rate: +63%, growth has picked up over the last three years. Years of annual history on file: 9, FY2017 to FY2025, as filed.

BBIOBridgeBio Pharma, Inc.

Healthcare

$65.35+25% 1Y

$65.35

$49.0052 weeks$85.86

Is it growing?

Good

Growing: revenue growing +202% year on year and operating margin widening (+2690.8 points).

2 good, 1 without data

Revenue trend+202% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +63% a year.

Margin direction+2690.8 points operating

Trailing-twelve-month operating margin, -77.3% now against -2768.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is BBIO growing?

BridgeBio Pharma, Inc. has grown revenue 401% a year over three years and 63% a year over five.

+401%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +63%
Revenue growth, 5-year rate · +401% over three · growth has picked up over the last three years
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed

Details›